| INTRODUCTION
Neuraminidase inhibitors (NAIs) are the mainline therapy of influenza. 1 Through binding in the conserved catalytic domain of the enzyme, these drugs can inhibit all types and subtypes of influenza neuraminidase, but to varying degrees. 2 In recent years, the human influenza A viruses have developed complete resistance to an older class of drugs, the adamantanes, indicating the ability of these viruses to develop and subsequently maintain resistance to antivirals. 3 In the first years of NAIs usage, following their introduction in 1999, naturally occurring resistance was sporadically reported and a very limited number of cases were described. [4] [5] [6] [7] However, in 2008, naturally occurring oseltamivir resistance was detected among seasonal H1N1 viruses in Norway. 8 This resistant virus eventually displaced the NAI-susceptible H1N1 virus rendering virtually all seasonal H1N1 viruses highly resistant to oseltamivir. 8, 9 This emergence was not related to the use of antivirals. 10 
| MATERIAL AND METHODS

| Study design and conduct
Influenza Resistance Information Study (IRIS; NCT00884117) is a 7-year prospective, multicentre, observational study. Recruitment During the first 5 years of the study, inclusion centres were located in Europe (France, Germany, Norway, Poland), USA, China (Hong Kong) and Australia. Enrolment was carried out during 5 northern and 4 Southern Hemisphere influenza seasons. The study was performed in compliance with the principles of the Declaration of Helsinki and its amendments, and in accordance with Good Clinical Practice. The study protocol and amendments were approved by independent ethics committees and institutional review boards at each centre.
| Patient inclusion and virological analysis
During this study period, the criteria for inclusion were as previously described. 13 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , and summed to produce a total symptom score as previously described. 
| Biostatistical analysis
Kaplan-Meier plots were generated for time to viral RNA clearance and time to resolution of all diary card symptoms (no single symptom score of >1 on diary card). The statistical analysis was carried out by either Kruskal-Wallis or Wilcoxon signed-rank tests.
| RESULTS
During the 5-year surveillance period, 3230 patients with a single influenza strain infection were recruited. All study centres enrolled patients, the majority of whom (75.3%) were from the Northern In 27/43 (62.8%) of samples in which resistance first appeared, viral loads were too low for phenotyping (Table 2a , Table 2a and b).
In a significant number of cases (24/27 H1N1pdm2009 and 15/16 H3N2), the resistant virus detected by the mutation-specific RT-PCR, contained a mixed population of H275/Y275 or R292/K292
for at least one time point (Table 2a and virus clearance, with a median of 8.1 days for the treated patients vs 9.9 days for the non-treated patients (P < .0001) and 10.9 days for the treated patients with a resistant virus (P < .0001) (Figure 3) .
Similarly, the time to alleviation of symptoms was 1 day shorter in treated patients as compared with non-treated patients (P < .0001, see Figure 4 ). However, despite the delayed virus clearance observed in patients infected with oseltamivir-resistant viruses, this group exhibited a shorter duration of symptoms (borderline significance: P = .024, Figure 4 ). Resistant viruses emerged during the treatment course. In all documented cases, the resistant virus remained detectable until the last positive detection, except for one H1N1pdm2009 (patient 11 
| DISCUSSION
In years 1-5 of the IRIS study, resistance to oseltamivir in influenza A viruses was not detected in the 2316 Day 1 samples analysed (except 14,20
In our study, the proportion of R292K substitutions in H3N2 viruses isolated (16/662, 2.4%) was relatively low as compared to Kiso et al. 21 The latter reported 9/50 (18%) of emerging resistant viruses during treatment in children with a first detection at day 4 of treatment. In our study, we report only 7.7% (10/129) of emerging resistance. This difference may be due to the recruitment of cases (majority of hospital cases in the Kiso study), the sampling procedures (nasal washes in some patients of the Kiso study vs swabs in our study) and the geographical distribution of our patients. However, we both support the idea that monitoring the resistance of influenza viruses requires analysis of sequential specimens collected in patients treated with oseltamivir. Surveillance with D1 samples only cannot provide a clear picture for an emerging resistance risk assessment, especially for H3N2 viruses.
According to analysis of the sequential specimens collected in these patients, resistant viruses emerged by Day 3 of treatment from susceptible strains and were selected by oseltamivir. It is known that the fitness of R292K H3N2 viruses is putatively severely impaired. 22 This detection of the R292K substitution was performed by a specific snip RT-PCR, a sensitive method that can detect down to 5% of a minority species. 15 It confirmed also that in most cases, a mixed population is detected, supporting the hypothesis that impaired NA activity of 292K viruses may be trans-complemented by the NA activity of R292 bystander viruses, as it has been reported for mutations at position 119. 23 The mutation-specific real-time RT-PCR used in the current study and HA or NA sequencing were performed on the original clinical specimen and not culture based or genetically assessed by sequencing on culture material. In the present study, of the 16 samples in which the R292K mutation was detected, only 5
could be cultured and subsequently tested phenotypically for NAI susceptibility. Two of them showed an increased IC 50 , while 3 had a normal IC 50 . This lack of detection of reduced inhibition may be due to the use of the Na-Star system (chemiluminescent assay) that is less sensitive than the gold standard MUNANA-based fluorescent assay. 24 The H275Y resistance in H1N1pdm09 was the most reported in this study (27/43 R-Viruses). This is consistent with the various reports about oseltamivir resistance in N1 viruses in general. This resistance emerged from Day 3 in 1/3 of the 27 cases, not only in children (Table 2b) . When, measured, the IC50 values were mostly reduced inhibition, and some were normal inhibition, due to mixed genotypes (H275 & 275Y) and the use of the chemiluminescent assay. The 
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